Apexus, a key contractor for the 340B drug pricing program, has come under scrutiny for profiting off its expanding role in the program, which was initially designed to help safety-net hospitals provide discounted drugs to low-income patients, The New York Times reported Jan. 15.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
